Headlines about Kamada (NASDAQ:KMDA) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kamada earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.2069999215412 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Kamada (KMDA) traded up $0.15 on Friday, hitting $5.65. 26,234 shares of the stock traded hands, compared to its average volume of 28,299. The firm has a market capitalization of $221.81, a PE ratio of -141.21 and a beta of 1.03. Kamada has a 1-year low of $3.75 and a 1-year high of $8.61. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.71 and a quick ratio of 2.73.
A number of research analysts have commented on KMDA shares. Zacks Investment Research cut shares of Kamada from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Jefferies Group reaffirmed a “buy” rating and issued a $7.00 target price on shares of Kamada in a research report on Thursday, October 12th. Finally, ValuEngine raised shares of Kamada from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $8.50.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.